Parkinson's vaccine trial aims to slow disease progression

NCT ID NCT06015841

Ongoing Disease control Sponsor: AC Immune SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a vaccine called ACI-7104.056 in 150 people with early-stage Parkinson's disease. The goal is to see if it is safe and helps the body fight a protein linked to Parkinson's. Participants must already be on stable low-dose levodopa. This is not a cure, but may help control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal recessive early-onset Parkinson disease 6 Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE PARKINSON DISEASE 6, EARLY-ONSET

Contacts and locations

Locations

Hospital De La Santa Creu I Sant Pau

Barcelona, Spain
Hospital Universitari Vall D Hebron

Barcelona, Spain
Hospital Universitario De La Princesa

Madrid, Spain
Hospital Universitario Puerta De Hierro De Majadahonda

Majadahonda, Spain
Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón, Spain
Katholisches Klinikum Bochum GmbH

Bochum, Germany
King's College Hospital NHS Foundation Trust

London, United Kingdom
Northern Care Alliance NHS Foundation Trust

Salford, United Kingdom
Paracelsus-Kliniken Deutschland GmbH & Co. KGaA

Kassel, Germany
Policlinica Gipuzkoa

Donostia / San Sebastian, Spain
Re:Cognition Health Limited

London, United Kingdom
University Medical Centre Schleswig-Holstein

Kiel, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.